ArticleResearch and practice in thrombosis and haemostasis2026
The effects of recombinant human activated factor VII and tranexamic acid on traumatic bleeding and mortality in mice.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid (TXA) and recombinant human activated factor (F)VII (rhFVIIa) both control severe traumatic bleeding, with mortality benefit only demonstrated for TXA. Objectives: To compare the effects of rhFVIIa and TXA on bleeding, trauma-induced coagulopathy (TIC), inflammation, and survival in a murine trauma model. Methods: Liver laceration (LL) was employed to induce TIC. C57BL/6J mice were pretreated intravenously with saline, rhFVIIa (3 mg/kg), or TXA (10 mg/kg). Blood loss, coagulopathy (activated partial thromboplastin time [aPTT], FII, FV, FVIII, FX, thrombin-antithrombin [TAT], and fibrinogen), and fibrinolysis (tissue-type plasminogen activator, plasmin-α2-antiplasmin complexes, and D-dimer) were analyzed 60 minutes after LL. Cytokines were measured at 60 minutes and 6 hours. Pulmonary fibrin deposition and survival were evaluated for up to 7 days. Results: Both rhFVIIa and TXA reduced blood loss compared with saline-treated mice after LL. Saline-treated mice developed TIC (prolonged aPTT, increased TAT complex formation, and selective depletion of FV, FVIII, and fibrinogen). rhFVIIa overcorrected the aPTT and increased TAT complex levels, whereas TXA normalized these parameters. Both agents reduced tissue-type plasminogen activator and plasmin-α2-antiplasmin complex formation; however, rhFVIIa failed to suppress D-dimer formation and exacerbated interleukin-6 formation. Pulmonary fibrin deposition and microthrombi occurred exclusively in rhFVIIa-treated mice (days 1, 2, and 7), accompanied by reduced survival (∼50%) compared with TXA (∼80%). Conclusion: While both agents reduced bleeding, rhFVIIa promoted prothrombotic and inflammatory responses, which were associated with increased mortality. Our findings highlight the unmet need for targeted interventions to reduce TIC while minimizing thromboinflammatory risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.